Exclusive Summary

• UB031 is a First-in-Class anti-cMet x anti-Her2 Bispecific ADC, designed to address tumor heterogeneity and antigen escape, with broad anti-cancer potential.
• In vitro studies demonstrate its superior killing efficacy against various cancer cell lines compared to monospecific ADCs, with significant efficacy shown in pancreatic and lung cancer xenograft models.
• UB031 exhibits a favorable safety profile with a 10-10,000-fold therapeutic window observed in non-human primate studies, suggesting manageable toxicity at effective clinical doses.
• From a development perspective, UB031 has robust CMC properties, utilizes a well-established MMAE payload manufacturing process, and has a PCT patent application, indicating global market potential.
• By targeting cMet and Her2, UB031 holds promise as a breakthrough therapy for cancers with high unmet medical needs, such as pancreatic, lung, gastrointestinal, and renal cancers.

Asset Materials

Contact Us for Full Materials